RecruitingDrug trialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder CancerThis is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.